Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Prostatic Neoplasms 1Precancerous Conditions 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Breast Neoplasms 1Basal Cell Nevus Syndrome 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Comparative Genomic Hybridization × Clear all
NCT00070278 2013-08-07

Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
800 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡